SCHEMBL8750384

SCHEMBL8750384

CCc1ccccc1COC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
MGLL Q99685 1/20 0.35
CACNA1G O43497 1/20 0.35
CACNA1H O95180 1/20 0.35
KCNH2 Q12809 1/20 0.35
CACNA1C Q13936 1/20 0.35
CACNA1I Q9P0X4 1/20 0.35
SGMS2 Q8NHU3 2/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
TSHR P16473 1/20 0.33
HPGD P15428 1/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647871 0.91 IDO1 (0.38) GABRA1GABRB2CACNA1GCACNA1HKCNH2
SCHEMBL22361574 0.83 L3MBTL1 (0.33) L3MBTL1MAPTNPSR1SLC6A2SLC6A4
SCHEMBL10151283 0.83 IDO1 (0.35) L3MBTL1NPSR1CACNA1GCACNA1HKCNH2
SCHEMBL16446710 0.81 KDM4E (0.41) IDO1
SCHEMBL28647178 0.80 L3MBTL1 (0.33) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL12936636 0.78 TAAR1 (0.43) ADRA2AADRA2BADRA2CTSHRIDO1
SCHEMBL22391547 0.78 RIPK1 (0.44) CACNA1GCACNA1HKCNH2CACNA1CCACNA1I
SCHEMBL22957776 0.78 MCL1 (0.42) MAPTSLC6A2SLC6A4CACNA1GCACNA1H
SCHEMBL18184950 0.77 ALDH1A1 (0.36) SLC6A2SLC6A4ADRA2BIDO1
SCHEMBL14744531 0.77 IDO1 (0.55) MAPTTSHRIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879889-B2 administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease SANOFI-AVENTIS (FR) 2011-02-01 US disclosed
US-20090253753-A1 Therapeutic Use of Acylaminothiazole Derivatives SANOFI-AVENTIS (FR) 2009-10-08 US disclosed
US-7563903-B2 Acylaminothiazole derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2009-07-21 US disclosed
US-20080058380-A1 ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2008-03-06 US disclosed
US-7288659-B2 Acylaminothiazole derivatives, their preparation and therapeutic use SANOFI-AVENTIS (FR) 2007-10-30 US disclosed
EP-0523697-B1 Color-developing compositions and their use MITSUI TOATSU CHEMICALS (JP) 1997-04-02 EP disclosed
EP-0268878-B1 Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents MITSUI TOATSU CHEMICALS (JP) 1996-01-31 EP disclosed
US-5447901-A Color-developing sheet: base material coated with composition of /a/ multivalent metal-modified salicylic acid resin formed from salicylic acid, a benzyl compound and optional styrene and /b/ analogous resin free of salicylic acid MITSUI TOATSU CHEMICAL, INC. (JP) 1995-09-05 US disclosed
US-5376615-A Pressure sensitive elements containing a salicylic acid resin and a phenolic resin MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1994-12-27 US disclosed
EP-0523697-A1 Color-developing compositions and their use MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-01-20 EP disclosed
US-5023366-A Reacted with a benzyl halide, alcohol or ether; for pressure sensitive elements MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1991-06-11 US disclosed
EP-0268878-A2 Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253753-A1 Therapeutic Use of Acylaminothiazole Derivatives ACAT1, GLS2, GLS GABRA1 2009/4885GABRB2 1387/4885L3MBTL1 1882/4885
US-20080058380-A1 ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE PARK7, ACAT1, APP GABRA1 2970/4885GABRB2 3245/4885L3MBTL1 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.